Head-To-Head Review: MDxHealth (NASDAQ:MDXH) & Evaxion A/S (NASDAQ:EVAX)

MDxHealth (NASDAQ:MDXH) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Risk & Volatility

MDxHealth has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MDxHealth and Evaxion A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1	4	1	0	2.00
Evaxion A/S	1	0	4	0	2.60

MDxHealth currently has a consensus price target of $1.33, suggesting a potential upside of 749.26%. Evaxion A/S has a consensus price target of $11.25, suggesting a potential upside of 285.27%. Given MDxHealth’s higher possible upside, research analysts plainly believe MDxHealth is more favorable than Evaxion A/S.

Institutional and Insider Ownership

11.0% of Evaxion A/S shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares MDxHealth and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Evaxion A/S	N/A	-61.43%	-34.23%

Earnings & Valuation

This table compares MDxHealth and Evaxion A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$114.02 million	0.07	-$33.52 million	($0.72)	-0.22
Evaxion A/S	$7.49 million	3.52	-$7.71 million	($1.21)	-2.41

Evaxion A/S has lower revenue, but higher earnings than MDxHealth. Evaxion A/S is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.